The hardening of the facial skin is considered to be scleroderma, and the etiology of the disease may be related to genetics, infections and other factors. For patients with limited scleroderma, the prognosis is better after general treatment and drug therapy. The etiology of the disease is unknown. Genetic factors, autoimmunity, vascular damage and abnormal collagen synthesis may all be involved in the pathogenesis of systemic scleroderma. Limited scleroderma may be associated with trauma or infection. Central to its pathogenesis is the abnormal activation of fibroblasts, which synthesizes excess collagen, leading to fibrosis of the skin and internal organs. Patients may develop localized hard spots or patches in the form of bands, dots, or patches, and the face may also show signs of localized induration. Patients with scleroderma should maintain a good mood and avoid emotional excitement in their daily life. Patients can use topical glucocorticosteroids such as halometasone and mometasone furoate, which play an immunosuppressive role, and can take immune preparations such as cyclosporine A and methotrexate, which can reduce the extent of the disease by suppressing the activity of the immune system. Patients with limited scleroderma have a better prognosis after standardized treatment. For patients suffering from scleroderma, it is recommended to go to regular hospitals for examination and treatment under the guidance of doctors. Drugs need to be used in accordance with medical advice.